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ABSTRACT 
 
INTRODUCTION: 
Breast cancer is now the most common cancer in woman .There are several 
factors which influence the development of breast malignancies such as the genetic 
background,  reproductive parameters and the consequences of female hormones 
both intrinsic and extrinsic. Numerous studies have examined prognostic factors for 
survival of breast cancer patients, but relatively few have dealt specifically with 
relationship between hormonal receptor status, BMI and lymphovascular invasion. 
 
AIM AND OBJECTIVES: 
To study the correlation between hormonal receptors status (ER, PR, HER 2 
NEU) and other prognostic factors like age, node, BMI, menopausal status, 
lymphovascular invasion in carcinoma breast 
 
METHODOLOGY: 
All patients who fulfill the inclusion criteria were included in the study after 
obtaining written informed consents. Patient age, body mass index, tumour size, 
node, menopausal status is noted. The histopathology, ER, PR and HER-2/neu 
receptor status and lymphovascular invasion are obtained from trucut biopsy and 
specimen. The correlation of these prognostic factors was observed in our study. 
 
  
RESULTS: 
The mean age of carcinoma of breast was 48.5 years of age in our study. 
Positive receptor status(ER, PR & BOTH ER& PR) is strongly associated with 
normal BMI and decreased lymphovascular invasion. Negative receptor status(ER, 
PR & BOTH ER& PR) is strongly associated with obese patients and increased 
lymphovascular invasion in carcinoma breast.Normal BMI is associated with 
decreased lymphovascular invasion and obese BMI patients are associated with 
increased lymphovascular invasion in both pre and post-menopausal women. HER 
2 NEU receptor status and node have no significant association with lympho 
vascular invasion and body mass index. 
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INTRODUCTION 
Carcinoma breast is one of the most common carcinoma occurring in 
females. It is a major illness that affects the female physically and mentally. In 
India, it is the leading cancer among women. Chennai ranks third (32.6) among 
Indian states. India has the highest number of breast cancer deaths in the world 
(70218) followed by China (47984) and USA (43909).  
The final outcome in breast cancer management depends upon various 
prognostic factors  
• Age 
• Tumour size 
• Lymph nodes  
• Receptor status 
• Lymphovascular invasion 
• Body mass index 
 
Early diagnosis and treatment will decrease the morbidity and mortality 
of the disease significantly. The treatment depends upon the patient at which 
stage they are presenting to the health services. The breast cancer management 
requires a multi-modality approach, which includes surgery, radiotherapy, 
chemotherapy, hormonal therapy. 
In this study, we planned to study the correlation of the various 
prognostic factors such as age, BMI, receptor status, node and lymphovascular 
invasion in patients with carcinoma of breast. 
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AIMS AND OBJECTIVES 
 
• To evaluate the correlation of prognostic factors such as age, Body mass 
index,ER, PR HER 2 receptor status in patients with carcinoma of breast 
 
• To study the correlation between hormonal receptors status and other 
prognostic factors with lymphovascular invasion in carcinoma breast 
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REVIEW OF LITERATURE 
ANATOMY OF THE BREAST: 
        The breast is a modified sweat gland. In 7th week of intrauterinelife, they 
are derived from the ectodermal milk lines bilaterally. Breast is an accessory 
reproductiveorgan. They are made of glandular tissue containing 15 to 
20lobes.  Each lobe is made up of group of alveoli and it is drained by 
lactiferousduct. Each duct has a dilatation called lactiferous sinusat its 
termination beneath thenipple. Group of alveoli draining intoduct is called 
Primary secretory unit. Myoepithelium is a single layer of epithelial cells 
surrounds only the ducts not lining thelobules. They are contractile and aid the 
transport of secretions along the duct. Major part of thegland has fatty stroma. 
 
 
Fig 1: Anatomy of breast
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Fig: 2 Development of breast 
Plane: 
The breast lies superficial to the pectoral fascia. 
Extent: 
Vertically- Second to the sixth rib 
Horizontally- the lateral border of the sternum to mid-axillary line lies over 
the following muscles: 
• Pectoralis major  
• Serrartusanterior 
• External oblique of the abdomen. 
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Axillary tail of Spence: 
Extension of the breast that passes through the foramen of Langer and 
therefore this part of breast is deep to the fascia. It has direct contact with 
lymph node. 
 
Ligament of cooper: 
Anchored to the overlining skin and to the underlying fascia by bands 
of these connective tissues. 
 Nipple: 
Nipple is located at the level of fourth intercostal space. It is pierced by 
15 to 20 lactiferous ducts which open independently to nipple. The stiffness of 
nipple mainly due to circular and longitudinal muscles in it. 
Areola: 
Areola is a circular pigmented area around nipple. They are rich in 
modified sebaceous glands. They secrete oily lubricant. 
Blood supply of the breast: 
The breast is rich in vascular supply. 
• Internal mammary artery- a branch of subclavianartery 
• Lateral thoracic 
• Superior thoracic                  Branches of the axillaryartery 
• Acromiothoracic  
• Posterior intercostal arteries 
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Venous supply: 
 The veins follow the arteries. Superficial veins drains into the 
internal thoracic vein whereas the deep veins drains into the internal thoracic, 
axillary and posterior intercostal veins. 
The communication of posterior intercostals veins with the Batson’s 
vertebral venous plexus is the basis of spread of breast malignancy to 
vertebra and skull base. 
Nerve supply: 
• Anterior cutaneous branches of the 4th to 6th intercostals 
nerves  
• Lateral cutaneous branches of the 4th to 6th intercostals nerves.  
• Sensory fibres to skin 
• Autonomic fibres to blood vessels and smooth muscle. 
Lymphatic drainage of breast: 
Lymph from the breast drains into the following nodes. 
 Axillary nodes 
 Level 1:lateral to pectoralis minor 
 Includes anterior or pectoralgroup, posterior 
orsubscapulargroup, lateral or humeralgroup 
    Level 2: posterior to pectoralis minor - Centralgroup 
 Level 3:medial to pectoralis minor - apical group 
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 Internal mammary (parasternal nodes) 
- situated along internal thoracic vessels 
 Interpectoral or rotters nodes: between pectoralis major and minor. 
 Supraclavicularnodes 
 Cephalic(deltopectoral)nodes, 
 Posterior intercostalsnodes 
 Subdiaphragmatic and subperitoneal lymphplexuses. 
 Few lymphatic pierce the pectoral fascia & enter thechest 
Pattern of drainage: 
• 75% drains into axillary nodes 
• 20% drains into internal mammary nodes  
• 5% drains into posterior intercostalnodes. 
• Among the axillary nodes, the anterior group drains mostly followed by 
the posterior and apical group. 
• The internal mammary nodes drain the lymph from both inner and outer 
half of breast. 
• A plexus of lymph vessels- sub areolar plexus of Sappey is present deep 
to theareola. 
• Lymphatics from the deeper surface of the breast pass through the 
pectoralis major muscle and the clavipectoral fascia to reach the apical 
nodes and also to theinternal mammary nodes. 
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• Lymphatics from the lower and inner quadrants of thebreast crosses the 
costal margin and pierces the anterior abdominal wall through the upper 
part of linea Alba and communicate with the subdiaphragmatic and 
subperitoneal lymph plexuses. 
 
PHYSIOLOGY OF BREAST: 
• Estrogen -ductal development 
• Progesterone -epithelium and lobular development.  
• Prolactin - lactogeneis during late pregnancy and the postpartum 
period.  
Prolactin results in the upregulation of hormone receptors and aids 
in epithelial development.     
Positive and negative feedback mechanisms exercise stringent 
control of the hormones secreted from the hypothalamus and thepituitary. 
Dramatic changes are noted in the female breast changes during 
various developmental stages in adolescence, pregnancy, lactation and 
senescence. The complex interactions among the various hormones are 
responsible for these changes. Imbalances in these hormones result in 
several conditions both benign and malignant. 
 Fig 3: Regulation of Breast Development & Function
 
Fig 4: Physiological stages of breast development
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CLINICAL PRESENTATION:  
Women with carcinoma breast will present with the following complaints: 
• Lump in the breast with or without nipple 
retraction– most common 
•  An axillary nodemass. 
• Symptoms due to metastaticdisease 
                      Liver – abdominal pain / mass / obstructive jaundice 
               Lung – breathlessnes, cough with hemoptysis, 
pleural effusion 
               Bone – pain over long bone site   
• Discharge from nipple – rare presentation 
• Skin changes:  
 Paeu d’orange 
   Is due to cutaneous lymphaticoedema. As the lymphtics 
are blocked there is lymphatic oedema of the overlying skin and infiltrated skin 
is tethered by the sweat glands. 
It can’t swell there by giving an orange peelappearance. 
 Ulceration 
 Satellite nodule 
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RISK FACTOR FOR BREAST CANCER: 
Age: 
Age is probably the most important risk factor for breast 
cancerdevelopment. The incidence of breast cancer continues to increase with 
advancing age of the female population. Breast cancer is rare in women 
younger than 20 years and constitutes less than 2% of the total cases. 
Thereafter, the incidence increases to 1 in 233 from ages 30 to 39 years, 1 in 69 
from ages 40 to 49, 1 in 42 from ages 50 to 59, 1 in 29 from ages 60 to 69, and 
1 in 8 by age 80 years. The women now have an average risk of 12.2% of being 
diagnosed with breastcancer at some time during their lives. 
Sex: 
Sex is also an important risk factor because most breast cancers occur in 
women. Breast cancer also occurs in men. Incidence of breast cancer in men is 
less than 1% of the incidence in women. 
Personal History of Breast Cancer: 
 The magnitude of risk depends on the age at diagnosis of the first 
primary cancer, estrogen receptor (ER) status of the first primary cancer and 
use of adjuvant systemic chemotherapy and endocrine therapy 
Histologic Risk Factors: 
Histologic abnormalities diagnosed by breast biopsy constitute an 
important category of breast cancer risk factors. These abnormalities include 
lobular carcinoma in situ (LCIS) and proliferative changes with atypia. LCIS is 
an uncommon condition that is observed predominantly in younger 
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premenopausal women. It is typically an incidental finding at biopsy for 
another condition and does not manifest as a palpable mass or suspicious 
microcalcifications on mammography. 
 
HISTOLOGICAL DIAGNOSIS – RR 
 Nonproliferative disease - 1.0 
 Proliferative disease without atypia  1.3-1.9 
 Proliferative disease with atypia    3.7-4.2 
 Strong family history   4-9 
 LCIS     >7 
 
Family History of Breast Cancer and Genetic Risk Factors: 
The relationship between family history of breast cancer and the risk for 
breast cancer is a proven one. First-degree relatives (mothers, sisters, and 
daughters) of patients with breast cancer have a twofold to threefold excess risk 
for development of the disease. Risk is much higher if aﬀected first-degree 
relatives had premenopausal onset and bilateral breast cancer. Risk is not 
significantly increased in women with distant relatives (cousins, aunts, 
grandmothers) with breast cancer 
 
GENETIC FACTORS: 
Genetic factors are estimated to be responsible for 5% to 10% of all 
breast cancer cases, but they may account for 25% of cases in women younger 
than 30 years.   
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The BRCA1 gene which was identified in chromosome 17(17q21). 
Mutations in BRCA1account results for 40% of familial breast cancers. The 
BRCA2 which was identified in chromosome 13 account for 30% of familial 
carcinoma. In addition to carcinoma breast these patients have additional risk 
for other carcinoma. 
 
Reproductive Risk Factors: 
Reproductive milestones that increase a woman’s lifetime estrogen 
exposure are thought to increase her breast cancer risk. These include 
• Onset of menarche before 12 years of age 
• First live childbirth after age 30 years 
• Nulliparity 
• Menopause after age 55 years. 
 There is a 10% reduction in breast cancer risk for each 2-year delay in 
menarche; the risk doubles with menopause after age 55. A first full-term 
pregnancy before age 18 years is associated with half the risk for development 
of breast cancer of a first full term pregnancy after age 30 years. In contrast to 
family history or histologic factors, reproductive risk factors have a large 
influence on breast cancer. 
Exogenous hormone use: 
Therapeutic or supplemental estrogen and progesterone are taken for 
various conditions. The two most common reasons are contraception in 
premenopausal women and HRT in postmenopausal women. Other indications 
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for use of exogenous hormones include menstrual irregularities, polycystic 
ovaries, fertilitytreatment, and hormone insufficiency states. 
Studies have suggested that breast cancer risk is increased in current or 
past usersof oral contraceptives but that the risk decreases as the interval 
after cessation of use increases. 
These data show that women receiving combination HRT with estrogen 
and progesterone for 5 years have approximately a 20% increased risk for the 
development of breast cancer. 
 Women who take estrogen-only formulations (because of previous 
hysterectomy) do not appear to be at increased risk for breast cancer 
 
Non modifiable risk Factors: 
• Increasing age 
• Female sex 
• Menstrual factors 
• Early age at menarche (onset of menses before age 12 yr) 
• Older age at menopause (onset beyond age 55 yr) 
• Nulliparity 
• Family history of breast cancer 
• Genetic predisposition (BRCA1 and BRCA2 mutation carriers) 
• Personal history of breast cancer 
• Race, ethnicity (white women have increased risk compared with 
women of other races) History of radiation exposure 
15 
 
Modifiable risk factors: 
• Reproductive factors 
• Age at frst live birth (full-term pregnancy after age 30 yr) 
• Parity 
• Lack of breastfeeding 
• Obesity 
• Alcohol consumption 
• Tobacco smoking 
• Use of hormone replacement therapy 
• Decreased physical activity 
• Shift work (night shifts) 
 
Histologic Risk Factors: 
• Proliferative breast disease 
• Atypical ductal hyperplasia 
• Atypical lobular hyperplasia 
• Lobular carcinoma in situ 
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STAGING OF CARCINOMA: 
Non - invasive Epithelial Cancers 
• Lobular carcinoma in situ 
• Ductal carcinomain situ or intraductal carcinoma 
 Papillary 
 cribriform 
 solid  
 comedo  
 
Invasive Epithelial Cancers  
Invasive lobular carcinoma (10%) 
Invasive ductal carcinoma: 
• Invasive ductal carcinoma, not otherwise specifed (50%-70%) 
• Tubular carcinoma (2%-3%) 
• Mucinous or colloid carcinoma (2%-3%) 
• Medullary carcinoma (5%) 
• Invasive cribriform carcinoma (1%-3%) 
• Invasive papillary carcinoma (1%-2%) 
• Adenoid cystic carcinoma (1%) 
• Metaplastic carcinoma (1%) 
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Mixed Connective and Epithelial Tumors: 
• Phyllodes tumors, benign and malignant 
• Carcinosarcoma 
• Angiosarcoma 
• Adenocarcinoma 
 
TNM STAGING: 
Primary tumour (T): 
TX - Primary tumor cannot be assessed  
T0 - No evidence of primary tumor 
Tis - Carcinoma in situ 
 Tis (DCIS) DCIS 
 Tis (LCIS) LCIS 
 Tis (Paget) Paget disease of the nipple not associated with invasive carcinoma 
or carcinoma in situ (DCIS and/or LCIS) in underlying breast parenchyma 
 
 T1 Tumor ≤ 2 cm in greatest dimension 
 T1mi  Tumor ≤1 mm in greatest dimension 
 T1a  Tumor >1 mm but ≤5 mm in greatest dimension 
 T1b  Tumor >5 mm but ≤10 mm in greatest dimension 
 T1c  Tumor >10 mm but ≤20 mm in greatest dimension 
T2 Tumor>2cm but ≤5cm in greatest dimension 
T3 Tumor>5cm in greatest dimension 
18 
 
T4 Tumor of any size with direct extension to the chest wall and/or to the skin 
T4a  Extension to the chest wall, not including only pectoralis muscle 
adherence    or invasion 
T4b  Ulceration and/or ipsilateral satellite nodules and/or edema of the skin 
 T4c Both T4a and T4b 
 T4d Inflammatory carcinoma 
 
Regional Lymph Nodes (N):  
Clinical stating 
Nx Regional lymph nodes cannot be assessed (e.g., previously removed) 
No regional lymph node metastases 
N1 Metastases to movable ipsilateral level I, II axillary lymph node(s) 
N2 Metastases in ipsilateral level I, II axillary lymph nodes that are clinically 
fixed or matted; or in clinically detected* ipsilateral internal mammary nodes in 
the absence of clinically evident axillary lymph node metastases 
N2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one 
another (matted) or to other structures 
 N2b  Metastases only in clinically detected* ipsilateral internal mammary 
nodes and in the absence of clinically evident level I, II axillary lymph node 
metastases 
N3 Metastasis in ipsilateral infraclavicular (level III axillary) lymph node(s) 
with or without level I, II axillary lymph node involvement; or in clinically 
detected* ipsilateral internal mammary lymph node(s) with clinically evident 
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level I, II axillary lymph node metastases; or metastases in ipsilateral 
supraclavicular lymph node(s)  with or without axillary or internal mammary 
lymph node involvement 
N3a Metastasis in ipsilateral infraclavicular lymph node(s) 
N3b Metastasis in ipsilateral internal mammary lymph nodes(s) and axillary 
lymph node(s) 
N3c Metastasis in ipsilateral supraclavicular lymph node(s) 
 
Pathological classification: 
 
pNX Regional lymph nodes cannot be assessed 
pN0 No regional lymph node metastasis 
pN0 (i-) No regional lymph node metastasis histologically, negative IHC 
pN0 (i+) Malignant cells in regional lymph nodes no greater than 0.2 mm 
pN0 (mol-) No regional lymph node metastasis histologically, negative 
molecular findings (IHC)  
pN0 (mol+) Positive molecular fndings (RT-PCR), but no metastasis detected 
by histology or IHC 
 
pN1 Micrometastases; or metastases in 1-3 axillary nodes and/or in internal 
mammary nodes with metastases detected by sentinel lymph node biopsy 
but not clinically detected 
pN1mi Micrometastases (>0.2 mm and/or >200 cells but none >2.0 mm) 
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pN1a Metastases in 1-3 axillary nodes; at least one metastasis >2.0 mm 
pN1b Metastases in internal mammary nodes with micrometastasis or 
macrometastases detected by sentinel lymph node biopsy (not clinically 
detected) 
pN1c Metastases in 1-3 axillary nodes and in internal mammary nodes with 
micrometastases or macrometastases detected by sentinel lymph node biopsy 
but not clinically detected 
 
pN2 Metastases in 4-9 axillary nodes or in clinically detected internal 
mammary lymph nodes in the absence of axillary lymph node metastases. 
pN2a Metastases in 4-9 axillary nodes (at least one tumor deposit >2.0 mm)  
pN2b Metastases in clinically detected internal mammary lymph nodes in the 
absence of axillary lymph node metastases 
 
pN3 Metastases in ≥10 axillary nodes; or in infraclavicular (level III axillary 
nodes) or in clinically detected ipsilateral internal mammary lymph nodes in 
the presence of one or more positive level I, II axillary nodes; or in >3 axillary 
lymph nodes and internal mammary lymph nodes, with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but not clinically 
detected; or in ipsilateral supraclavicular lymph nodes. 
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Metastasis: 
M0 No clinical or radiographic evidence of distant metastases 
cM0(i+) No clinical or radiographic evidence of distant metastases, but 
deposits of molecularly or microscopically detected tumor cells in circulating 
blood, 
bone marrow, or other nonregional nodal tissue that are no larger than 0.2 mm 
in a patient without symptoms or signs of metastases 
M1 distant detectable metastases as determined by classic clinical and 
radiographic means and/or histologically proven larger than 0.2 mm 
 
Table 1: Staging of carcinoma breast 
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PROGNOSTIC FACTORS: 
AGE  
Age place an important factor in the prognosis of carcinoma breast 
.Women diagnosed with breast cancer in their early age have a poorer 
prognosis than women diagnosedinmiddle or olderage. There as on for this 
unusual pattern is unclear. According to literature breast cancer occurring in 
younger women is of more aggressive type. 
 
They are usually, 
• large size tumour 
• Node positivity 
• High grade 
• Poorly differentiated 
• High tumor invasive potential 
• Greater chances of early lymphatic spread 
• ER,PR negative, Her2 positive 
 
Thus,thepoorer outcome could at least partly be due to differences in 
these important prognostic factors.Recurrence of the tumour is also more 
common in younger women than elderly women. In this study we studied the 
mean age of occurrence of tumour, receptor status at various ages. 
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OBESITY 
Obesity adversely affects women’s health.Obesity in women is a 
recognized risk factor for metabolic syndrome, type II diabetes mellitus, 
cardiovascular disease and several major cancers including breast and 
endometrial cancer. The risk of breast cancer increases with obesity and also 
associated with poor prognosis of breast cancer. Obesity is measured as weight 
gain, body mass index, waist–hip ratio or percent body fat. In our study obesity 
is measured in terms of BMI. A one-point gain in BMI is estimated to increase 
the risk of postmenopausal breast cancer by 3%.There are several mechanisms 
by which body weight and obesity affect the prognosis of breast cancer. 
 
Fig: 5 
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Hormones: 
 The breast cancer survivors, who are obese, have higher bio available 
concentrations of tumour promoting hormones such as estrogen and 
testosterone, which may contribute to poor survival. Obese women have 35% 
higher concentrations of estrogen and 130% higher concentrations of estradiol 
and increased Testosterone concentrations compared with nonobese woman. 
Obesity is strongly and inversely associated with sex-hormone-binding 
globulin (SHBG)levels,suggestingthatcentralobesitywithassociated 
lowplasmalevelofSHBGspromotesbioavailabilityofandro- gens and estrogen. 
 Obese women may have hyperinsulinemia that promote mammary 
carcinogenesisbyincreasingthelevelsofinsulin-likegrowthfactor. (IGF), free 
fatty acid and leptin which have a synergistic effect to estrogen on mammary 
epithelial cells by promoting angiogenesis and transcriptionalfactors.Leptin, a 
type of adipocytokines that are produced by adipocytes have been associated 
with carcinogenesis, tumour migration and invasion, enhancement of 
angiogenesis and increased aromatase activity.  
Nutrition: 
 The association between breast cancer risk and dietary factors has long 
been recognised but the complex relationship between obesity, nutrition and 
breast cancer is not fully understood. The regular physical activity after a 
breast cancer diagnosis has a strong evidence toreducethe risk of death from 
this disease but there is little direct evidence to show that lack ofphysical 
exercise leads to the development or poor prognosis of breast cancer. 
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TUMOUR SIZE: 
Tumour size is one of the strongest prognostic indicators. When tumours 
are detected at their early stage we can perform a breast conserving surgery. 
When tumour size are larger it implies more number of tumour doubling time 
and the chance of distance metastatis is also high.A larger tumour has been 
related to more positive lymph nodes , thus their interaction further influences 
the survival . Tumour size plays an important role in deciding neo adjuvant 
chemotherapy. In this study the mean tumour size in premenopausal women 
and post menopausal women and their relation with BMI are studied.   
AXILLARY LYMPH NODE: 
Axillary lymph node status is one of the most important prognostic 
factors for breast carcinoma and a valuable indicator of long-term survival. 
Node- positive patients have about a 4–8 times higher mortality than those 
without nodal involvement. The more nodes involved the worse the prognosis. 
  Lymphnode clearance in mastectomy surgery depends on the positivity 
of node. Practice has changed from full dissection and/or radiation of the axilla 
to the use of sentinel node biopsy (SNB) for many patients. There is still debate 
about what constitutes an adequate axillary dissection in terms of the total 
number of lymph nodes removed. It is generally accepted that greater than 10 
LNs are required .One study found that at least five and 10 nodes are required 
for node-negative and node-positive patients respectively. The LN ratio (LNR), 
defined as the number of positive LNs over the number of LNs removed. LNR 
places an important prognostic ratio. 
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RECEPTOR STATUS: 
The breast cancer is a heterogeneous disease with variable biological 
and clinical characteristics because of its different genetic make-up. It is well 
known that Proto-oncogenes and tumor suppressor genes are two classes of 
genes that play a central role in the regulation of cell growth and 
differentiation. So any alterations in one or more of these genes appear to play 
an important role in the pathogenesis of most human malignancies. 
 
ESTROGEN RECEPTOR: 
 
 
Fig: 6 
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Estrogen receptors (ERs) are a group of proteins found inside cells. 
They are activated by the hormone estrogen (17β-estradiol).Two types (G 
protein-coupled receptors) 
• 1.ERα 
• 2.ERβ 
MECHANISM OF ACTION: 
ER receptors, once activated by estrogen translocate into nucleus and 
binds to the DNA. This regulates the activity of different genes. 
Distribution: 
The ERα are found in 
• Breast cancer cells  
• Endometrium 
• Ovarian stromal cells  
• Hypothalamus. 
• Efferent duct epithelium (males). 
The ERβ are found in 
• ovarian granulosa cells 
• heart 
• lungs 
• prostate 
• intestinal mucosa, endothelial cells 
• Kidney, brain and bone. 
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The affinity differs with different ligands for binding to alpha and beta 
isoforms of the estrogen receptor. The agonistic and antagonistic effects of 
Selective estrogen receptor modulators (SERMs) at selective sites are mainly 
due to selective binding to either alpha or beta subtype of the receptor. 
The ratio of α- to β concentration is important in certain 
diseases.Tamoxifen is an antagonist in breast but an ER agonist in bone and is, 
therefore, used as a breast cancer treatment and also prevent osteoporosis. But 
it increases the risk of endometrial cancer due to its partial agonistic action 
atendometrium.In around 70% of breast cancer cases, estrogen receptors are 
over- expressed and they are referred to as "ER-positive". 
ER POSITIVE  TUMOUROGENESIS 
TwoHypotheses has been described: 
1. When estrogen binds to ER receptors, the proliferation of mammary 
cells get stimulated leading to increase in cell division and DNA replication. 
This leads to mutation. 
2. Estrogen metabolism produces genotoxic waste leading to mutation. 
Both these processes leads to Disruption of the cell cycle, apoptosis and DNA 
repair Tumor formation 
Other cancers associated with estrogen and its receptor is 
• ovarian cancer 
• endometrial cancer 
• colon cancer 
• Prostate cancer. 
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The concept of SERMs is based on the ability to initiate the interactions 
of estrogen receptors with the proteins such as 
• transcriptionalcoactivators 
• Transcriptionalcorepressors. 
 
Different tissues has different ratio of coactivator to corepressor 
protein. Thus the same ligand may be 
• agonist where the coactivatorspredominate 
• antagonistic where the corepressors predominate 
 
PROGESTERONE RECEPTOR: 
Fig: 7 
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The progesterone receptor (PR) also known as NR3C3 is a protein 
found inside cells. It is activated by the steroid hormone progesterone.In 
humans, PR is encoded by a single PGR gene residing on chromosome 11q22. 
Three forms  
• PR-A 
•   PR-B,  
•   PR-C. 
 The PR-B - positive regulator  
 PR-A and PR-C - antagonize the effects of PR-B 
• No binding hormone in receptor  the carboxyl terminal of the 
receptor inhibits transcription. 
•  Binding in receptor hormone  structural change in the receptor  
removes the inhibitory action of the carboxyl terminal.  
• Progesterone antagonists prevent the structural reconfiguration of the 
receptor. 
After progesterone interacts with its receptor, dimerization occurs and 
the Pg- PgR complex enters into the nucleus and then binds to DNA.It leads 
to transcription and then formation of mRNA that is translated      by the 
ribosomes to produceproteins. 
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Her 2 neu (erbb2) receptors: 
HER-2/neu proto-oncogene (also called c-erbB2) is located on chromosome 
17q11, which encodes for p185 a transmembrane glycoprotein with 
tyrosinekinase activity that belongs to the family of epidermal growth factor 
receptors. 
HER2 can dimers with their receptors leading to phosphorylation of the 
tyrosine residues and initiates a variety of signaling pathways. It promotes 
cell proliferation and also opposes apoptosis. 
                        HER-2/neu proto-oncogene amplification or over expression is 
one of the most important alterations encountered in breast cancer. The 
amplification or over expression of HER-2/neu may lead to following: 
• Largetumor size 
•  high grade 
•  lack of steroid receptor expression 
•  axillary lymph nodes metastasis 
•  advanced stage,early relapse 
• Reduced overall survival. 
Increased recurrence rateHER2/neu proto-oncogene is amplified and or 
over expressed in approximately in 25-30% of invasive primary breast  
cancers .An association have become important because only patients 
with tumors that over express HER-2/neu benefit from antibody-based 
therapy with trastuzumab. For that reason, the determination of HER-
2/neustatus in breast cancer is becoming more important 
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Fig: 7 
The estrogen, progesterone and the Her2 neu receptors are estimated 
from the tissue sample using immunohistochemistry technique. Hormone 
receptors were considered negative whenconcentration was below 10%. P53 
was consideredpositive when nuclear staining was positive in morethan 10% 
of tumoral cells. HER-2/neu overexpressionwas considered positive when 
complete and intensemembrane staining was observed in more than 10%of 
tumor cells. 
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LYMPHOVASCULAR INVASION: 
Lymphovascular invasion (LVI) is defined as tumor emboli present 
within a definite endothelial-lined space in the breast surrounding invasive 
carcinoma. The existence of LVI may help identify who is at increased risk for 
axillary lymph node and metastasis.Lymphovascular invasion (LVI) is 
currently considered as an important prognostic factor for primary breast 
cancer. Previously it was reported that LVI is an independent prognostic factor 
for disease-free survival (DFS) and overall survival (OS) of patients with breast 
cancer. 
Moreover, LVI was associated with the development of lymph node 
metastases and lymphatic micro vessel density. Another clinical study 
conducted by Krishnamurti et al showed that LVI may be associated with 
peripheral tumor-infiltrating lymphocytes, which have a clinical significance in 
breast cancer. A recent study by showed that breast cancer subtypes could 
affect the outcomes relatedto LVI.  The prognosis of hormone receptor-
negative breast  cancers, such as TNBC, is suggested to be highly 
influenced by LVI compared to that of hormone receptor-positive breast 
cancers. 
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INVESTIGATIONS:  
NONINVASIVE TESTS 
MAMMOGRAPHY: 
Conventional mammography delivers a radiation dose of 0.1 cGy per 
study.  
By comparison, chest radiography delivers 25% of this dose.  
However, there is no increased breast cancer risk associated with the 
radiation dose delivered with screening mammography. 
Two types 
• Screening. 
• Diagnostic. 
SCREENING MAMMOGRAPHY: 
• Screening mammography is used to detect unexpected breast cancer in 
asymptomatic women 
• It supplements history taking and physical examination. 
• For screening mammography two views of the breast are performed. 
 Medio lateral oblique (MLO). 
 Craniocaudal 
(CC) 
• The MLO view images the greatest volume of breast tissue, including 
the upper outer quadrant and the axillary tail of Spence.  
• The CC view provides better visualization of the medial aspect of the 
breast and permits greater breast compression.  
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• But because of lower specificity of single view screening 
most radiologists believe that screening examination 
should include both MLO and CC views. 
DIAGNOSTIC MAMMOGRAPHY: 
• Diagnostic mammography is used to evaluate women with abnormal 
findings such as a breast mass or nipple discharge.  
• Four views: 
 Medio lateral oblique (MLO). 
 Craniocaudal (CC). 
 90-degree lateral   
 spot compression  
• The 90-degree lateral view is used along with the CC view to triangulate 
the exact location of an abnormality.  
• Spot compression may be done in any projection by using a small 
compression device, which is placed directly over a mammographic 
abnormality that is obscured by overlying tissues. Breast compression is a 
must in mammography because 
 Holds breaststill. 
 Brings objects closer tofilm. 
 Separates overlapping tissue that might obscure 
underlyinglesions. 
 Decreases radiation dose ofmammography. 
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Disadvantages of mammography: 
      Pain 
      Uncomfortable due to compression of breast 
NORMAL FINDINGS: 
 Breast entirely fat. 
 Scattered fibro glandular densities. 
 Breast tissue is hetero genetically dense. 
 Extremely dense. 
 
ABNORMAL FINDINGS: 
 Micro stippled calcifications 
 Dense stellate soft tissue mass with irregular margin 
and spicky projection 
 Bilateral asymmetrical distribution of fibro glandular 
tissue. 
 Architectural distortion 
 Increased thickness of skin due to lymphedema 
 Nipple retraction. 
 Axillary LN enlargement. 
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DIGITAL MAMMOGRAPHY: 
This type records the radiography image electronically in a digital 
format rather than a film. It is left in computer and is displayed on 
fluorescentmonitor. 
 
ULTRASOUND: 
• It is useful in evaluation of dense breast 
• For screening or diagnostic in women less 
than 40 years 
• To differentiate b/w cystic and solid masses. 
Unfortunately 
Masses that are smaller than 5 to 10 mm may not be visualized. 
MRI: 
• No radiation exposure 
• To differentiate scar from recurrence 
• Breast with implants 
• Screening of high risk woman in younger 
age 
• Very small lesion can be determined 
• Choice of imaging in pregnant female 
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INVASIVE TESTS: 
ASPIRATION CYTOLOGY: 
It uses fine needle with a syringe to aspirate cells from a suspicious area 
 smearing them on a glass slide  fixing them immediately (to prevent air 
drying)  staging for cytology.  
22-23gauge needle attached to syringe is used. The air dried preparation 
slide is stained with wrights /wrights Giemsa / May Grunnwald Giemsa. If not 
air-dried it is immediately fixed with 95% alcohol and staining is done with H 
& E stain / with pap stain. 
Combination of physical examination, mammography and FNAC will 
produce a diagnostic accuracy approaching 100%.FNAC is done in palpable 
mass, mass on mammogram. Sensitivity of test is approximately 80%; false 
negative varies b/w 2-10 %.  
COMPLICATIONS OF FNAC:  
• Growing out of tumor along needle tract, which is less in case of 
caliber<20 gauze. 
• Acutemastitis. 
• Pneumothorax. 
• Haematomas. 
• Interval of 2 weeks required between FNAC and mammography as 
they form hematomas and result in false positive mammographic 
studies. 
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CORE NEEDLE BIOPSY:  
• Standard of care for biopsy of breast lesion 
• 11G core needle isused. 
• More invasive – more number of wedge of tissues are 
taken 
• Able to differentiate invasive and in situ lesions 
• Receptor status are assessed 
• Lymphovascular lesion and grade of tumour are also 
assessed 
• Betteraccuracy 
 
OPEN BIOPSY:  
Excision: 
• When lump is less than 4 cm 
• Removal of whole lump with 1 cm of clearance. 
Incisional: 
• When core biopsy is inconclusive 
• Incision should be within the boundary of 
mastectomy scar 
• No diathermy should be used 
 
Galactography:   
Injection of contrast into one of the ducts through the orifice of the 
areola. It may demonstrate ductal ectasia, obstruction / fillingdefect. 
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TREATMENT OF CARCINOMA BREAST: 
For treatment purpose carcinoma breast is divided into 3  
• Early breast cancer 
• Locally advanced carcinoma breast 
• Metastatic  breast  carcinoma 
EARLY CARCINOMA BREAST 
Includes -  
T1N0, T2NO, T1N1, T2N1, T3NO 
The main mode of treatment in early breast carcinoma is breast conservative 
surgery. It includes 
BREAST CONSERVATIVE SURGERY:  
• wide local excision of tumour  
• axillary sampling  
• post op radiotheraphy  
• Regular follow up. 
The breast specimen that is removed is oriented before sent for 
pathology. This allows focal reexcision of involved margins rather than global 
reexcision and thus improves the cosmetic result. The surgical defect created 
after lumpectomy is closed in cosmetic fashion by using advancement flap 
closure method. 
Surgical staging of the axilla is performed through a separate incision in 
most patients undergoing breast conservation. Anatomic axillary node 
dissection in replaced by selective lymph nodal excision in clinically negative 
axillary nodes. 
41 
 
FACTORS INFLUENCING BREAST CONSERVATION SURGERY: 
Tumor Size. 
 Lumpectomy is considered regardless of size of tumour, if can be 
excised with clear margins and an acceptable cosmetic result. 
Tumors 5 cm in size, clinically positive nodes and tumors with lobular 
and ductal histology were included in therandomized trials of mastectomy 
versus breast-conserving therapy 
 
Margins: 
 The positive margins were associated with a twofold 
increase in ipsilateral breast tumor recurrence risk compared with 
negativemargins. The clinicopathologic features, biology, endocrine therapy, 
administration of radiotherapy have no significant effect 
 
Histology 
Invasive lobular cancers and cancers with an extensive intraductal 
component can be treated with lumpectomy if clear margins canbe achieved. 
Atypical hyperplasia (ductal and lobular) and LCISat resection margins do not 
increase local recurrence rates. 
Patient Age 
Local recurrence rates after breast-conserving surgery are higher 
for younger women than for older women. The use of radiation therapy 
reduces local recurrence in patients of all ages. 
All patients undergoing breast conservation surgery should 
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receive radiotheraphy post operatively. Any patients who have 
contraindication for RT are not the candidate for breast conservation 
theraphy. 
CONTRAINDICATION FOR RADIOTHERAPHY 
Absolute 
• Pregnancy 
Relative 
• Systemic scleroderma* 
• Active systemic lupus erythematosus* 
• Prior radiation to breast or chest wall 
• Severe pulmonary disease 
• Severe cardiac disease (if tumor is left-sided) 
• Inability to lie supine 
• Inability to abduct arm on affected side 
• p53 mutation† 
 
TABLE: 2 
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Fig: 8 
 
  Tumor that require mastectomy are following 
•  large tumour breast ratio 
• Tumors with extensive calcifications on mammography 
• tumors for which clear margins cannot be  obtained on wide local 
excision 
• tumors in patients with contraindications to breast irradiation 
• Patient preference for mastectomy or a desire to avoid radiation is also a 
valid indication for mastectomy. 
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MODIFIED RADICAL MASTECTOMY: 
Modified radical mastectomy refers to removal of  
• The mammary gland  
• nipple and areola 
• Axillary lymph node dissection (level 1 and 2 sometimes 
level 3) (ALND). 
An elliptical skin incision is planned to include the nipple and areola and 
usually any previous excisional biopsy scars.  Skin flaps are raised to separate 
the underlying gland from the overlying skin along the sub dermal plexus. 
 If immediate reconstruction is not planned, sufficient skin is taken to allow 
smooth closure of skin flaps without redundant skin folds; this facilitates 
comfortable use of breast prosthesis. 
If immediate reconstruction is planned, a skin-sparing mastectomy may 
be performed in which only the nipple-areola complex is removed and the 
maximum amount of skin is left for use in the reconstruction. 
 
Fig: 9 
 
  
LOCALLY ADVANCED CARCINOMA BREAST:
 
METASTATIC CARCINOMA BREAST:
•  Only palliative care
• Toilet mastectomy
• Palliative chemotheraphy and radiotheraphy
 
 
 
 
OPERABLE
MRM
ADJUVANT CHEMOTHERATHY
RADIOTHERAPHY
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LABC
INOPERABLE
NEOADJUVANT CHEMOTHRAPHY
MRM
ADJUVANT CHREMOTHERAPHY 
RADIOTHERAPHY
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CHEMOTHERAPHY: 
It is give as 3 forms 
• Neo adjuvant 
• Adjuvant 
• Palliative  
Despite advances in surgical treatment, most of the woman develops 
metastasis with in 5 to 10 years. Hence chemotherapy is a most 
important modality of treatment in carcinoma breast. 
Most common used are anthracyclins and taxanes. 
Most common regimen used is CMF regimen (cyclophosphamide, 
Methotrexate, 5- fluorouracil 
Other regimens are CAF, AC, and CEF. 
 
Table: 3 
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RADIATION THERAPHY: 
Radiotherapy is mainly for locoregional control of disease. It is given as 
• Adjuvant therapy 
 Brest conservation surgery 
 MRM 
• Palliative therapy 
Target volume: 
AFTER BCS  
• Whole breast RT 
• Lumpectomy boost 
• Regional nodes 
AFTER MASTECTOMY 
• Chest wall 
• Scar 
• Regional nodes 
DOSE OF RADIATION 
Conventional: 
50 Gy in 25 daily fractions - 5 weeks 
Hypo fraction: 
40 Gy in 15 daily fractions 2.65 Gy - 3 weeks 
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BREAST BOOST RADIATION TO TUMIUR BED: 
16 Gy in 8 daily fractions- 1.5 weeks 
10 Gy in 5 daily fractions- 1 week 
 
LYMPH NODE RADIATION: 
50 Gy in 25 daily fractions - 5 weeks 
40 Gy in 15 daily fractions - 3 weeks 
 
PALLIATIVE DOSE: 
30 Gy / 10# 
8 Gy / 1# 
 
 
Fig 10 
 
 
 
 
  
 
 
METHODOLOGY 
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METHODOLOGY: 
Study Design Observational study (Prospective) 
Sample Size 160 
Inclusion Criteria 
All the carcinoma breast patients diagnosed clinically and 
confirmed by trucut biopsy undergoing MRM 
BODY MASS INDEX – 16 to 40(Normal to severely 
obese) 
BMI: 16 -25 Normal 
BMI: 25 – 40 Overweight and obese 
Exclusion Criteria 
Advanced carcinoma of breast 
Carcinoma breast with metastasis 
Undergoing neoadjuvant chemotherephy 
Very severely obese patients(BM >.40) 
Severely underweight (BMI <16) 
Ethics Clearance Applied 
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Investigations 
All Patients who fit the inclusion criteria will be observed 
and following data collected 
 
• USG breast (age less than 40 years) / mammogram 
of other breast (age more than 40 years) 
• Trucut biopsy 
• CT Chest 
• Skeletal survey/ Bone scan 
• USG abdomen  
 
METHODOLOGY 
All patients who fulfill the inclusion criteria will be 
enrolled.  
Written informed consents will be obtained.  
 Biopsy proven patients only will be included in the study.  
Trucut biopsy will be taken and samples were submitted 
for histopathology, determination of estrogen, 
progesterone receptor expression and HER-2/neu status. 
Associations with other characteristics like age, 
menopausal status, body mass index, tumour size, and 
node will also be studied. 
I will do the investigations mentioned above. 
Will stage the carcinoma breast based on TNM 
classification Based on staging will proceed with modified 
radical mastectomy followed by adjuvant theraphy. 
The resected segment will be sent for histopathology to 
study the lymphovascularinvolment. 
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SAMPLE SIZE CALCULATION: 
  
Based on the study titled “comparison of ER, PR and HER-2/neu (c-
erbB2) reactivity pattern with histologic grade, tumour size and lymph node 
status in breast cancer done by Azizun - Nisa, bhurgri Y, Raza F Kayani N 
 
When Z = 1.96 for α 0.05; P= 24.7; q = 75.3 d is fixed as 7% 
  = 146 
Assuming a non response rate of 10%, sample size is fixed at 146+14=160 
The collected data were analysed with IBM.SPSS statistics software 
23.0 Version. To describe about the data descriptive statistics frequency 
analysis, percentage analysis were used for categorical variables and the 
mean & S.D were used for continuous variables. To find the significance in 
categorical data Chi-Square test was used similarly if the expected cell 
frequency is less than 5 in 2×2 tables then the Fisher's Exact was used. The 
Odds ratio and relative risk was used to find the effect of cause. In all the 
above statistical tools the probability value .05 is considered as significant 
level.  
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RESULTS 
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RESULTS 
 
About 160 women who were affected with carcinoma breast were 
included in this study based on my inclusion and exclusion criteria. All women 
are biopsy proven carcinoma breast and underwent surgery as primary 
treatment. 
 
AGE DISTRIBUTION: 
Among the 160 women, 40(25%) were under 40 years, 56(35%) were 
between 41 to 50 years, 41(25.6%) were between 51 to 60 years, about 20 
(12.5%) were between 61 to 70 years and only 3 (1.9%) were above 70 years. 
Thus most of the patients in my study were between 41 to 50 years. 
AGE Frequency Percent 
Valid Up to 40 yrs. 40 25.0 
41 - 50 yrs. 56 35.0 
51 - 60 yrs. 41 25.6 
61 - 70 yrs. 20 12.5 
Above 70 yrs. 3 1.9 
Total 160 100.0 
 
Table: 4 
 
 
  
 
Mean age of women getting carcinoma breast in my study is 48.57 years 
of age. 
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In my study, i took the women having BMI between 16 to 25 as normal 
and BMI between 26 to 40 as obese. Among 160 women, 89(55.6%) were 
normal BMI whereas
 
Valid
 
Table: 5 
 
 
 
 
In my study the mean BMI value of woman getting carcinoma breast 
was 25.019 years of age.
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BMI: 
 71(44.4%) were obese.  
BMI 
Frequency Percent 
 Normal 89 55.6 
Obese 71 44.4 
Total 160 100.0 
Graph: 2 
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In my study
menopausewhereas 
menopause. 
Among the 160 carcinoma patients 74(46%) patients have 
lymphovascular invasion where remaining 86(54%) has no lymphovascular 
invasion. 
55 
MENOPAUSAL STATUS: 
, 86(54%) women had breast cancer after 
74(46%) of women had breast cancer before attaining 
Graph: 3 
LYMPHOVASCULAR INVASION 
Graph: 4 
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ER, PR AND HER 2 NEU RECEPTOR STATUS: 
In this study of 160 carcinoma breast women, 54% has ER receptor 
positive status, 60 % has PR receptor positive status and 49.4 % has HER 2 
NEU receptor positive status. Among them 36.3% have both ER, PR receptor 
positive status. 
 
 
 
ER Positive
45.6
46%
ER NEGATIVE
54.4
54%
0
0%
ER STATUS IN CA BREAST
ER Positive
ER NEGATIVE
PR 
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40.0
40%PR 
Negative
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PR Negative
 Descriptive Statistics 
In  this study the following mean values are observed
 
N
AGE_A 160
HEIGHT 160
WEIGHT 160
BMI 160
Valid N  
(list wise) 
160
HER 2 NEU 
Negative, 49.4
, 0
HER 2 NEU STATUS IN CA BREAST
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Graph: 5 
 
 
 Minimum Maximum 
 24 76 
 143 171 
 40 86 
 19.0 34.4 
   
 
Table: 6 
HER 2 NEU 
Positive, 50.6
HER 2 NEU Positive
HER 2 NEU Negative
 
Mean 
Std. 
Deviation 
48.74 9.812 
155.10 5.786 
60.08 9.229 
25.019 3.6763 
  
  
CORRELATION DATAS:
        In this study on carcinoma breast the following prognostic factors were 
correlated and their relationship was
1. Receptor status with lymphovascular 
 ER receptor status with lymphovascula
In this study among the patient with lymphovascular invasion, 
(77%) has negative ER receptor status whereas 
invasion majority show
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 studied. 
invasion: 
r invasion: 
those without lymphovascular 
 positive ER receptor (65.1%) status. 
Graph: 6 
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 PR RECEPTOR STATUS WI
 
In this study among the patient with lymphovascular invasion, 
(86.5%) has negative PR receptor status whereas 
invasion majority show
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TH LYMPHOVASCULAR INVASION:
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HER 2 NEU RECEPTOR STATUS WITH LYMPHOVASCULAR 
INVASION: 
 
In this study among the patients having lymphovascular invasion, 
44.60% has positive HER 2 NEU status whereas 55.4 % has HER 2 NEU 
negative status. 
 
 
GRAPH: 8 
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BOTH ER, PR RECEPTOR STATUS WIT
Among the patients affected with lymphovascular invasion only 13.5 % 
shows positive ER, PR
receptors status has no lymphovascular invasion.
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 2. Receptor status with
 
ER RECETOR STATUS VS BMI:
In this study 
positive status has normal BMI where
negative ER receptor status 
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 BMI: 
 
75.3 %( majority) of carcinoma breast patients 
as only 24.7 % are obese 
majority (60.9%) were obese. 
Graph: 10 
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 PR RECETOR STATUS VS BMI:
In this study 79.63 %( majority) of carcinoma breast patients with PR 
positive status has normal BMI whereas 23.4 % are obese
negative PR receptor status 58.3% were obese.
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 HER 2 NEU RECETOR STATUS VS BMI
In this study among the patients having POSITIVE HER 2 NEU, 
%( majority) has normal BMI whereas 38.3% are obese.
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 BMI VS LVI: 
Among the patients who has 
71.6 % (majority) are obese with BMI mo
lymph vascular invasion 
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 BMI VS LVI VS MENOPAUSE:
Among the postmenopausal woman, positive lymphovascular invasion 
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tumor patients, 52% has normal BMI 
 (Obese). Among the node negativity 62% are 
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5. NODE VS LVI: 
Node positivity is noted in 75.7% of patients with lymphovascular 
invasion and 62.8% noted in patients without lymphovascular invasion. 
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ODDS RATIO AND P VALUES FOR VARIOUS PROGNOSTIC 
FACTORS 
  ODDS RATIO P VALUE 
ER STATUS BMI 0.210 0.0005 
PR STATUS BMI 0.219 0.0005 
HER 2 NEU STATUS BMI - 0.116 
ER STATUS LVI 0.160 0.0005 
PR STATUS LVI 0.093 0.0005 
HER 2 NEU STATUS LVI - 0.157 
BMI, 
PREMENOPAUSAL 
LVI 21.5 0.0005 
BMI, 
POSTMENOPAUSE 
LVI 9.53 0.0005 
NODE LVI 1.844 0.08 
NODE BMI 1.463 0.274 
 
Table: 7 
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DISCUSSION: 
 
In this observation study we studied the association between various 
prognostic factors of carcinoma breast like receptor status, BMI, 
lymphovascular invasion in both pre and post-menopausal women. 
 In this study the mean age of women with carcinoma breast was 48.57 
years of age which is almost closure to Mehdi tazhibi et al study. In this study 
most of the patients were between 40 to 50 years which is similar to chopra et 
al study from Punjab.  Thus most of the women with carcinoma breast are in 
their perimenopausal age. 
 In this study patient having BMI less than 25 were taken as normal and 
BMI more than 25 were taken as obese.  We found that BMI is a statistically 
significant independent risk factor of carcinoma breast. In our study majority of 
carcinoma breast patients with ER +ve, PR +VE , BOTH ER & PR +VE have 
normal BMI, whereas the majority carcinoma breast patients with ER-VE,PR-
VE, ER PR –VE status has BMI in obese range . This implies that  patients 
with normal BMI has more chance for positive receptor status which has a 
better prognostic value whereas obese patients were associated with more 
negative hormonal receptor status tumour which has comparatively poor 
response to treatment. This observation is comparable to previous study from 
America, which analyzed breast cancer mortality in the obese group relative to 
the normal weight. In a study including African patients, overweight was 
significantly related to breast cancer mortality by multivariable 
analysis. However this study is controversial to Kawai et al reported that 
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obesity was an independent risk factor for breast cancer death but had no 
association with breast cancer prognosis. 
We also correlate BMI with clinically palpable node. But there is no 
statistically significant association between node positivity and BMI. 
               In this study the lymphovascular invasion is more with obese (71.6 
%), which is an independent poor prognosis for carcinoma breast. In our study 
the lymphovascular invasion is more in both pre and post-menopausal women 
and it is statistically significant (p < 0.01) which implies increased BMI as a 
significant risk factor in both premenopausal and post-menopausalwomen.This 
observation is similar to kang lu et al study in post-menopausal status but 
controversial to pre-menopausalstatus, which showed the following inference, 
that for premenopausal women, higher BMI could decrease breast cancer risk 
but higher BMI is associated with increased breast cancer risk in 
postmenopausal women. 
 In jain et al  study 37.4%  patients, had ER positive status and 62.6%  
patients had ER negative status while 34%  patients had PR positive status and  
66% patients had PR negative, whereas in our study we have the following 
observation  54% has ER receptor positive status , 60 % has PR receptor 
positive status. Among them 36.3% have both ER, PR receptor positive status.  
In our study we compared the Receptor status with BMI and lymphovascular 
invasion. Our study concluded that in patients having positive receptor status 
like ER+VE/PR+VE/ER & PR+VE, majority are in the range of normal BMI 
and has significantly lower lymphovascular invasion whereas in patients 
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having negative receptor status majority has lymphovascular invasion and has 
BMI in obese range. 
This implies that positive receptor status is a good prognostic factor and 
chemotherapy can be effectively used as adjuvant therapy. This is comparable 
to the Dunnwald et al study, Vinita et al study which also concluded that 
ER/PR negative status has been associated with increased mortality. 
 Our study has 49.4 % HER 2 NEU receptor positive status which is 
comparable toJain et al study which has 35% positive status. There is no 
statistically significant association between HER2 NEU receptor status and 
lymphovascular relationship which is in contrast to Jain et al study. 
 Lymphovascular invasion is an important and independent prognostic 
factor of carcinoma breast. In our study 46% has lymphovascular invasion 
which was comparatively lower than young ju et al study. This may be due to 
larger sample study of that study. The lymphovascular invasion has statistically 
significant positive correlation with negative receptor(ER, PR, and ER&PR) 
status and BMI. But lymphovascular invasion was not statistically significant 
with HER 2 NEU and nodal status. This nodal status association is in contrast 
to young ju et al study. 
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CONCLUSION: 
 
 
• Incidence of breast carcinoma is high in peri menopausal age group  
(40 – 50 years of age). 
• In my study the following statistically significant  results were obtained: 
 Positive receptor status(ER, PR AND HER 2 NEU) is 
found in majority of the women with normal BMI and 
negative receptor status is associated with obese patients. 
 Positive receptor status(ER, PR) are associated with 
decreased lymphovascular invasion and negative receptor 
status is associated with increased lymphovascular 
invasion. 
 Normal BMI is associated with decreased lymphovascular 
invasion in both pre and post-menopausal women in 
contrast to obese patients. 
• Association of lymph node with lymphovascular invasion and body 
mass index is found to be statistically insignificant 
• Association of HER 2 NEU with lymphovascular invasion is statistically 
insignificant. 
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LIMITATIONS: 
 
• Our study involved only those women with carcinoma breast 
admitted in our surgical department; hence it does not reflect the 
data of the community. 
• Our study doesn’t include the patients with advanced carcinoma 
breast who were on neo adjuvant therapy. 
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QUESTIONAIRE 
 
PATIENT DETAILS: 
Name:     Age:   Sex:   
IP No:                           
ON ADMISSION: 
Chief COMPLAINTS:  
DURATION: 
ASSOCIATED COMPLAINTS: 
CLINICAL EXAMINATION: 
Height:                                                    Weight: 
Body mass index: [weight in kg/height in m2]  
Pulse :     BP : 
RR :      Temp : 
Pallor:     Icterus: 
CVS:      RS: 
P/A:      CNS: 
EXAMINATION OF BOTH BREASTS: 
 
EXAMINATION OF BOTH AXILLARY REGIONS: 
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INVESTIGATIONS: 
 
HB%     
PCV      
TC     
RBC     
PLATELETS     
RBS     
Urea     
Creatinine     
Na+/K+     
CXR: 
USG BREAST: 
MAMMOGRAM: 
USG ABDOMEN: 
CT CHEST: 
SKELETAL SURVERY: 
BONE SCAN: 
TRUCUT BIOPSY: 
STAGE: 
TREATMENT 
OPERATIVE MANAGEMENT: 
CHEMOTHERAPY: 
RADIOTHERAPHY: 
HPE REPORT: 
FOLLOW UP: 
LFT     
Total Bili     
Dir. Bili     
SGOT     
SGPT     
Total 
Protein 
    
Sr. Albumin     
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INFORMATION SHEET 
TITLE:“A STUDY ON CORRELATION BETWEEN ESTROGEN 
RECEPTOR, PROGESTERONE RECEPTOR, HUMAN EPIDERMAL 
GROWTH FACTOR RECEPTOR-2 STATUS AND OTHER 
PROGNOSTIC FACTORS IN CARCINOMA BREAST” 
Name of Investigator :Dr.M.HARINI 
Name of Participant: 
Study Procedure: Patient will be subjected to clinical examination, routine 
investigations, X-ray, Usg Breast/Mammogram, USG abdomen, CT chest, 
skeletal survey/bone scan. 
Possible Risks: No risks to the patient 
Possible benefits 
To patient: A better understanding of their problem so has to devise à plan of 
management which suits their needs. 
To doctor & to other people:  If this study gives positive results, it can help 
determine the prognosis of disease early which helps the doctor to plan the 
procedure correctly and their follow up with adjuvant systemic therapy. In 
future this will help in improving 10 year survival rate. 
Confidentiality of the information obtained from you: The privacy of the 
patients in the research will be maintained throughout the study. In the event of 
any publication or presentation resulting from the research, no personally 
identifiable information will be shared.Taking part in this study is voluntary. 
You are free to decide whether to participate in this study or to withdraw at any 
time.Your decision will not result in any loss of benefits to which you are 
otherwise entitled. 
 
Signature of Investigator    Signature of Participant 
 Date:                                          Place: 
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PATIENT CONSENT FORM 
 
 
 
 
 
 
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I have the opportunity 
to ask question and all my questions and doubts have been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the Ethics 
committee and the regulatory authorities will not need my permission to look at my health 
records, both in respect of current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study I agree to this access. However, I understand that 
my identity will not be revealed in any information released to third parties or published, unless 
as required under the law. I agree not to restrict the use of any data or results that arise from this 
study. ❏ 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or wellbeing or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study 
 
❏ 
I hereby give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical, radiological tests and to undergo treatment ❏ 
 
Signature / thumb impression     Signature of Investigator 
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